| Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial EP Winer, O Lipatov, SA Im, A Goncalves, E Muñoz-Couselo, KS Lee, ... The Lancet Oncology 22 (4), 499-511, 2021 | 314 | 2021 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 298 | 2021 |
| Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim … SRD Johnston, M Toi, J O'Shaughnessy, P Rastogi, M Campone, ... The Lancet Oncology 24 (1), 77-90, 2023 | 184 | 2023 |
| Cancer during pregnancy: The oncologist overview A Hepner, D Negrini, EA Hase, P Exman, L Testa, AF Trinconi, JR Filassi, ... World journal of oncology 10 (1), 28, 2019 | 151 | 2019 |
| KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) J Cortés, O Lipatov, SA Im, A Gonçalves, KS Lee, P Schmid, K Tamura, ... Annals of Oncology 30, v859-v860, 2019 | 117 | 2019 |
| Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast … EP Winer, O Lipatov, SA Im, A Goncalves, E Muñoz-Couselo, KS Lee, ... Journal of Clinical Oncology 38 (15_suppl), 1013-1013, 2020 | 56 | 2020 |
| Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated … S Loi, E Winer, O Lipatov, A Goncalves Cancer research 80 (4), 1158-1159, 2020 | 50 | 2020 |
| Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors R Ferrarotto, L Testa, RP Riechelmann, M Sahade, LT Siqueira, FP Costa, ... Rare tumors 5 (3), 121-125, 2013 | 48 | 2013 |
| Brazilian Cardio-oncology Guideline–2020 LA Hajjar, IBSS Costa, MACQ Lopes, PMG Hoff, MDPE Diz, ... Arquivos Brasileiros de Cardiologia 115 (5), 1006-1043, 2020 | 47 | 2020 |
| KEYNOTE-119: phase 3 study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (MTNBC) J Cortés, O Lipatov, S Im, A Gonçalves, SK Lee, P Schmid, K Tamura, ... Ann Oncol 30 (suppl_5), v851-v934, 2019 | 43 | 2019 |
| Return to work after breast cancer diagnosis: An observational prospective study in Brazil LCG Landeiro, DM Gagliato, AB Fede, NM Fraile, RM Lopez, ... Cancer 124 (24), 4700-4710, 2018 | 37 | 2018 |
| Diretriz Brasileira de Cardio-oncologia–2020 LA Hajjar, IBSS Costa, MACQ Lopes, PMG Hoff, MDPE Diz, ... Arquivos Brasileiros de Cardiologia 115 (5), 1006-1043, 2020 | 32 | 2020 |
| Biological therapies in breast cancer: common toxicities and management strategies R Barroso-Sousa, IA Santana, L Testa, D de Melo Gagliato, MS Mano The breast 22 (6), 1009-1018, 2013 | 31 | 2013 |
| Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the … M Martin, R Hegg, SB Kim, M Schenker, D Grecea, JA Garcia-Saenz, ... JAMA oncology 8 (8), 1190-1194, 2022 | 28 | 2022 |
| KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial EP Winer, O Lipatov, SA Im, A Goncalves, E Muñoz-Couselo, KS Lee, ... Lancet Oncol 22 (4), 499-511, 2021 | 25 | 2021 |
| Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer JA O'Shaughnessy, S Johnston, N Harbeck, M Toi, YH Im, M Reinisch, ... CANCER RESEARCH 81 (4), 2021 | 24 | 2021 |
| monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Ann Oncol 32 (12), 1571-1581, 2021 | 24 | 2021 |
| Câncer e Doenças Cardiovasculares na Pandemia de COVID-19 LT Kawahara, IBSS Costa, CCS Barros, GC Almeida, CS Bittar, SI Rizk, ... Arquivos Brasileiros de Cardiologia 115, 547-557, 2020 | 24 | 2020 |
| Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer ARK Sales, MV Negrão, L Testa, L Ferreira-Santos, RVR Groehs, ... American Journal of Physiology-Heart and Circulatory Physiology 317 (1), H1-H12, 2019 | 24 | 2019 |
| Impact of the COVID-19 pandemic on breast and cervical cancer stage at diagnosis in Brazil RC Bonadio, AP Messias, OA Moreira, LV Leis, BZ Orsi, L Testa, ... ecancermedicalscience 15, 2021 | 23 | 2021 |
